- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04255134
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) (BIORA-PAIN)
Comparison of Abatacept With Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis Pain: A Phase IV Trial
It is increasingly recognized that although suppression of inflammation is a treatment goal in rheumatoid arthritis, many people who have control of their inflammation continue to experience pain. A number of studies have recently shown that by measuring further characteristics of pain in rheumatoid arthritis, e.g. neuropathic pain, quantitative sensory testing, compared with objective measures of inflammation, it is possible to acquire more detailed information about the level of pain in relation to inflammation that a patient with rheumatoid arthritis is experiencing, which could assist in developing their care.
In this study, the investigators will explore validated endpoints for pain including the Visual Analogue Scale for pain, neuropathic pain scores and quantitative sensory testing for pain.
The investigators will evaluate in a population-based study, the pain profile using the Visual Analog Scale (VAS), neuropathic pain assessment, quantitative sensory testing (QST) by pain pressure thresholds (PPT) in comparison to markers of inflammation in order to assess the difference in pain outcomes between baseline pre- and post- treatment in a population of participants with active Rheumatoid Arthritis treated with abatacept and Tumor Necrosis Factor (TNF) inhibitors respectively. All measures will be conducted systematically in the abatacept and TNF inhibitor groups pre- and post-treatment with respective biologic agents. Participants with active Rheumatoid Arthritis who may be eligible for biologic treatment will be screened for enrolment into the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary objective To examine: Pain characteristics in participants with active rheumatoid arthritis receiving abatacept biologic therapy versus TNF inhibitor therapy in the form of adalimumab.
To establish if there are differences in pain outcomes by patient reported scores, objective measures of pain using quantitative sensory testing and inflammatory markers in participants receiving biologic therapies for rheumatoid arthritis.
Population: The population being assessed in this study are participants with active rheumatoid arthritis with a disease activity score of greater than 5.1.
Intervention: Subjects will be randomized to treatment with abatacept or adalimumab for active rheumatoid arthritis
Comparison group: Abatacept is being compared to adalimumab therapy in the trial
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Prof Sofat, MD, PhD
- Phone Number: 004402087251419
- Email: nsofat@sgul.ac.uk
Study Contact Backup
- Name: Ms Koushesh, BSc, MSc
- Phone Number: 004402082666474
- Email: skoushes@sgul.ac.uk
Study Locations
-
-
-
London, United Kingdom, SW17 OPQ
- Hotung Centre for Musculoskeletal Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Active rheumatoid arthritis causing pain and functional impairment with DAS28 >5.1 -Has already received usual care for inflammatory arthritis including conventional DMARD therapy e.g. methotrexate, sulfasalazine, leflunomide, hydroxychloroquine on stable dose of csDMARD for at least 4 weeks prior to study drug initiation
- Willing to participate in the study over a 12-month period
- Desirably to have positive antibodies to cyclic citrullinated peptide (ACPA/CCP)
- Between 18 and 75 years of age
Exclusion Criteria:
- Pregnancy or pregnancy planned over next 12 months
- Current or previous unsuccessful use of the biologics abatacept or adalimumab
- Co-existing other autoimmune condition, e.g. systemic lupus erythematosus, -Sjogren's syndrome, connective tissue disease, fibromyalgia, osteoarthritis, gout
- Recent surgery in the last 3 months or imminent surgery in the next 12 months
- Unable to give informed consent
- Previous history of cancer in the last 5 years
- Previous history of multiple sclerosis
- Uncontrolled heart failure, hypertension or diabetes mellitus
- Known history of fibromyalgia or other chronic pain disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abatacept
Drug administered to participants with active rheumatoid arthritis
|
Subjects will be randomized to treatment with either abatacept or adalimumab
Other Names:
|
Active Comparator: Adalimumab
Comparator drug administered to participants with active rheumatoid arthritis
|
Subjects will be randomized to treatment with either abatacept or adalimumab
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Visual Analogue Score for Pain
Time Frame: 0, 3, 6, 9, 12 months
|
The Visual Analogue Score for Pain is a pain score which has a numerical rating scale from 0 to 10
|
0, 3, 6, 9, 12 months
|
Change in the Neuropathic pain questionnaire: PainDETECT
Time Frame: 0, 3, 6, 9, 12 months
|
The painDETECT pain questionnaire is a numerical rated score for neuropathic pain
|
0, 3, 6, 9, 12 months
|
Change in Quantitative sensory testing
Time Frame: 0, 3, 6, 9, 12 months
|
Quantitative sensory testing measures numerical values for pain in specific regions of testing
|
0, 3, 6, 9, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Blood markers
Time Frame: 0, 3, 6, 9, 12 months
|
Pain biomarkers in serum
|
0, 3, 6, 9, 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prof Sofat, MD, PhD, St George's, University of London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Adalimumab
- Abatacept
Other Study ID Numbers
- 2019.0146
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on Abatacept Injection
-
Marmara UniversityThe Scientific and Technological Research Council of TurkeyRecruitingLRBA Deficiency | CTLA4 HaploinsufficiencyTurkey
-
Johns Hopkins UniversityBristol-Myers SquibbTerminated
-
University of Erlangen-Nürnberg Medical SchoolUnknown
-
Fundacion Clinic per a la Recerca BiomédicaActive, not recruitingPalindromic Rheumatism, WristSpain
-
Duke UniversityActive, not recruitingJuvenile Idiopathic ArthritisUnited States
-
Bristol-Myers SquibbCompletedUlcerative ColitisUnited States, Australia, India, Korea, Republic of, Poland, Canada, France, Brazil, Mexico, Puerto Rico, Belgium, Switzerland, Italy, Netherlands, Germany, Ireland, South Africa, United Kingdom, Czech Republic
-
University Medical Center GroningenBristol-Myers SquibbCompletedSjögren's SyndromeNetherlands
-
Melbourne HealthNational Health and Medical Research Council, Australia; Juvenile Diabetes...Active, not recruitingDiabetes Mellitus, Type 1 | Type 1 DiabetesAustralia
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedMultiple Sclerosis, Relapsing-RemittingUnited States, Canada